Notice of FY2006 Results

Oxford Biomedica PLC
27 February 2007







For Immediate Release                                           27 FEBRUARY 2007
                                                                            



             OXFORD BIOMEDICA: NOTICE OF FY2006 PRELIMINARY RESULTS

Oxford, UK - 27 February 2007: Oxford BioMedica (LSE: OXB), the leading gene
therapy company, announces that it will be releasing its preliminary results for
the twelve months ended 31 December 2006 on Tuesday, 6 March 2007.

Analyst meeting: An analyst briefing will be held at 10:00 am on 6 March at the
offices of Buchanan Communications, 45 Moorfields, London EC2.

Web cast: Simultaneously to the analyst briefing at 10.00 am, there will be a
live audio web cast of the results presentation. To connect to the web cast
facility, please go to the Company's website: http://www.oxfordbiomedica.co.uk/
approximately 10 minutes (09:50 am) before the start of the briefing. This will
also be available for replay shortly after the presentation.


-Ends-

For further information, please contact:
Oxford BioMedica plc:                                   Tel: [phone]
                                                                 
Professor Alan Kingsman, Chief Executive
City/Financial Enquiries:                               Tel: [phone]
                                                                       
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson Buchanan
Communications
Scientific/Trade Press Enquiries:                       Tel: [phone]
                                                                       
Gemma Price/ Holly Griffiths/ Katja Stout
Northbank Communications



Notes to editors


1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on oncology and
neurotherapy. The Company was established in 1995 as a spin out from Oxford
University, and is listed on the London Stock Exchange.


Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes two clinical candidates and a preclinical targeted antibody therapy,
which is being developed in collaboration with Wyeth. The Company has started
Phase III development of its lead cancer immunotherapy product, TroVax, in renal
cancer and multiple Phase II trials in various cancer settings are ongoing or
planned. In neurotherapy, the Company's lead product, ProSavin, is expected to
enter clinical trials in Parkinson's disease in 2007. The preclinical pipeline
includes gene-based products for vision loss, motor neuron disease and nerve
repair.


The Company is underpinned by over 80 patent families, which represent one of
the broadest patent estates in the field. The Company has a staff of
approximately 70 split between its main facilities in Oxford and its wholly
owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has
corporate collaborations with Wyeth, Intervet, Sigma-Aldrich, Viragen, MolMed,
and VIRxSYS; and has licensed technology to a number of companies including
Merck & Co, Biogen Idec, GSK and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk






                      This information is provided by RNS
            The company news service from the London Stock Exchange